Endpoints News
Genentech culls muscle-preserving drug in genetic diseases, raising questions about obesity trial
Roche’s subsidiary Genentech has called off the late-stage development of a muscle-building drug in two rare genetic conditions, spinal muscular atrophy (SMA) and facioscapulohumeral muscular dystrophy (FSHD).
The move raises questions about whether the drug …